Biotech execs predict big M&A deals ahead as mood shifts in wake of a 2018 hangover — Endpoints 100
It’s time once again to feel the pulse of the biotech industry.
In our latest survey of the Endpoints 100 — a collection of biotech execs dominated by CEOs of largely small and medium-sized companies — we gathered 80 responses. And they reflected a common sense of belief in the industry’s financial strengths at the start of 2019, the need for drug pricing reform, a general acceptance — with some big caveats — for the need to attend #JPM20 and a reevaluation of the way biotech assets will be valued and sold in the year ahead.
— A distinct surge of support for any changes in the drug pricing system we have now that would provide some added transparency for the public. The administration’s suggested end to rebates is generally popular.
— A pronounced level of caution over the hype we’re hearing regarding AI in drug discovery and development.
— A sense of duty accompanied by a deep-seated level of animosity regarding our annual migration to attend JPMorgan, topped by a layer of discontent when it comes to San Francisco sprinkled with a little gung-ho enthusiasm for limitless deal talks.
— A general sense of optimism for the year ahead, with a strong current of appreciation for access to capital and a major shift in sentiment regarding the E100’s evaluation of IPOs and biotech valuations even as M&A turns hot, hot, hot. The go-go days of 2018 are clearly over.
Who’s next on the M&A list? There’s no shortage of suggestions and plenty of forecasts that the Bristol-Myers/Celgene alliance won’t work out.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.